European perspectives on pediatric formulations

Area of Science:

• Pharmaceutical Sciences
• Regulatory Science
• Pediatric Medicine

Background:

• The European Union (EU) regulation enacted in 2007 seeks to address the historical lack of medicines for pediatric use.
• It aims to stimulate research and development through incentives, potentially improving the situation for children's medicines in the EU.

Purpose of the Study:

• To analyze the impact of the 2007 EU pediatric regulation on formulation science.
• To compare the EU's approach to pediatric drug formulation with that of the United States.

Main Methods:

• Literature search of MEDLINE and Chemical Abstracts from 1970 to October 2008.
• Keywords included pediatric drug formulations, age-appropriate dosage forms, child-appropriate medicines, and pediatric regulation.

Main Results:

• The 2007 EU legislation has spurred the creation of new organizations and networks focused on pediatric medicines and formulations.
• Novel EU measures, such as the Paediatric Investigation Plan and Paediatric Use Marketing Authorisation, were introduced, differing from US legislation.
• Pharmaceutical companies must adapt strategies to address EU-specific demands for early-stage pediatric formulation development, including age-appropriate choices, excipient selection, delivery devices, and taste prediction.

Conclusions:

• The 2007 EU legislation is anticipated to enhance the availability of child-appropriate drugs in Europe.
• Similar to the impact of US legislation, the EU's regulatory framework is expected to drive significant improvements in pediatric drug formulation research.